


To provide long-term capital growth from a portfolio primarily invested in UK equities.
| Name | % Net Assets |
|---|---|
| BG | 6.7% |
| Vodafone | 6.5% |
| GlaxoSmithKline | 5.2% |
| AstraZeneca | 4.6% |
| FirstGroup | 3.5% |
| Venture Production | 3.4% |
| Pearson | 3.1% |
| Scottish & Southern Energy | 3.0% |
| HSBC | 3.0% |
| RSA Group | 2.8% |
| Key | % Net Assets |
|---|---|
| 6.7% | |
| 6.5% | |
| 5.2% | |
| 4.6% | |
| 77% |
| Date | 20-Aug-2025 |
|---|---|
| NAV | 155.90p |
| Currency | GBP |
| Change | 0.83p |
| % | 0.54% |
| YTD change | 19.17p |
| YTD % | 14.02% |
| Fund Inception | 29/11/1999 |
|---|---|
| Fund Manager | Chris Watt |
| TER | 1.71 (31-Oct-2013) |
| Minimum Investment | |
|---|---|
| Initial | £500 |
| Additional | n/a |
| Savings | £100 |
| Charges | |
|---|---|
| Initial | 5.25% |
| Annual Mang't | 1.50% |
| Exit | n/a |
| Name | % |
|---|---|
| Standard deviation | 0.01 |
| Sharpe ratio | 0.27 |
You are here: research